SomnoMed (ASX:SOM) upgraded its revenue guidance for fiscal 2025 to roughly AU$105 million from AU$100 million, according to a Wednesday filing with the Australian bourse.
It also revised its earnings before interest, taxes, depreciation, and amortization (EBITDA) guidance to more than AU$7 million, up from a prior outlook of AU$5 million.
In the same filing, the company said it appointed Ye-Fei Guo as chief financial officer, effective immediately.
The company, which develops treatment products for sleep-related breathing disorders, saw shares climb almost 41% in afternoon trade Wednesday.
Price (AUD): $0.38, Change: $+0.11, Percent Change: +40.74%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.